Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D. Chretien AS, et al. Among authors: demerle c. Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747. Oncotarget. 2017. PMID: 28548938 Free PMC article.
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.
Chretien AS, Fauriat C, Orlanducci F, Galseran C, Rey J, Bouvier Borg G, Gautherot E, Granjeaud S, Hamel-Broza JF, Demerle C, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Gregori E, Luche H, Malissen M, Arnoulet C, Nunes JA, Vey N, Olive D. Chretien AS, et al. Among authors: demerle c. Front Immunol. 2017 May 29;8:573. doi: 10.3389/fimmu.2017.00573. eCollection 2017. Front Immunol. 2017. PMID: 28611767 Free PMC article.
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D. Chretien AS, et al. Among authors: demerle c. Oncotarget. 2019 Sep 10;10(52):5493. doi: 10.18632/oncotarget.27198. eCollection 2019 Sep 10. Oncotarget. 2019. PMID: 31534634 Free PMC article.
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, Wlosik J, Orlanducci F, Gorvel L, Fattori S, Hospital MA, Pakradouni J, Gregori E, Paul M, Rochigneux P, Pagliardini T, Morey M, Fauriat C, Dulphy N, Toubert A, Luche H, Malissen M, Blaise D, Nunès JA, Vey N, Olive D. Chretien AS, et al. Among authors: demerle c. Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2020459118. doi: 10.1073/pnas.2020459118. Proc Natl Acad Sci U S A. 2021. PMID: 34050021 Free PMC article.
Low frequency of Vγ9Vδ2 T-cells predicts poor survival in newly diagnosed acute myeloid leukemia.
Le Floch ACF, Orlanducci F, Béné MC, Ben Amara A, Rouviere MS, Salem N, Le Roy A, Cordier C, Demerle C, Granjeaud S, Hamel-Broza JF, Ifrah N, Cornillet-Lefebvre P, Delaunay J, Récher C, Delabesse E, Pigneux A, Vey N, Chretien AS, Olive D. Le Floch ACF, et al. Among authors: demerle c. Blood Adv. 2024 May 24:bloodadvances.2023011594. doi: 10.1182/bloodadvances.2023011594. Online ahead of print. Blood Adv. 2024. PMID: 38788176
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C, Gorvel L, Mello M, Pastor S, Degos C, Zarubica A, Angelis F, Fiore F, Nunes JA, Malissen B, Greillier L, Guittard G, Luche H, Barlesi F, Olive D. Demerlé C, et al. J Immunother Cancer. 2023 May;11(5):e006348. doi: 10.1136/jitc-2022-006348. J Immunother Cancer. 2023. PMID: 37230538 Free PMC article.
Chronic hepatitis E in absence of severe immune deficiency.
Colson P, Schleinitz N, Vely F, Poveda JD, Jacomo V, Demerle C, Borentain P, Gerolami R. Colson P, et al. Among authors: demerle c. Clin Res Hepatol Gastroenterol. 2020 Feb;44(1):e1-e4. doi: 10.1016/j.clinre.2019.06.015. Epub 2019 Jul 18. Clin Res Hepatol Gastroenterol. 2020. PMID: 31327621 No abstract available.
15 results